The new drug application (NDA) provides for the safe and effective use of Carbaglu in the treatment of hyperammonaemia due to an autosomal genetic disorder resulting in the deficiency of the liver enzyme N-acetylglutamate synthase.
The new drug application (NDA) provides for the safe and effective use of Carbaglu in the treatment of hyperammonaemia due to an autosomal genetic disorder resulting in the deficiency of the liver enzyme N-acetylglutamate synthase.